Herbert Kavunja
Principal investigator, leads IASO THERAPEUTICS, INC..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$4.1MFederal grants as PI6 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $4.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Mar 1, 2022 | NSF | SBIR Phase II SBIR Phase II:A Novel Bacteriophage Mutant as a Platform Carrier for Next Generation Vaccines | $1.4M | IASO THERAPEUTICS, INC. |
| Feb 24, 2022 | NSF | SBIR Phase II SBIR Phase II: A Novel Bacteriophage Mutant as a Platform Carrier for Next Generation Vaccines | $1.4M | IASO THERAPEUTICS, INC. |
| Jul 9, 2021 | NIH | SBIR Phase I Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine | $595K | IASO THERAPEUTICS, INC. |
| Sep 18, 2020 | NIH | SBIR Phase I A Novel Vaccine Strategy to Target Breast Cancer Enabled by Proprietary Mutant Bacteriophage Qbeta-Tumor Antigen Conjugates | $300K | IASO THERAPEUTICS, INC. |
| Jun 10, 2019 | NSF | SBIR Phase I SBIR Phase I: Development of Bacteriophage Qbeta and Mutants as Carriers for Next Generation Vaccines | $225K | IASO THERAPEUTICS, INC. |
| Jun 1, 2019 | NSF | SBIR Phase I SBIR Phase I: Development of Bacteriophage Qbeta and Mutants as Carriers for Next Generation Vaccines | $225K | IASO THERAPEUTICS, INC. |
Peer ranks
Federal funding#378
Awards as PI#315
Patents#273
Companies
- IASO THERAPEUTICS, INC.Leads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.